Arrestins as Regulators of Kinases and Phosphatases - Progress in Molecular Biology and Translational Science - page 136

ACKNOWLEDGMENTS
Supported in part by National Institutes of Health Grant DK55524 (L. M. L.) and the
Research Service of the Charleston, SC Veterans Affairs Medical Center. The contents of
this chapter do not represent the views of the Department of Veterans Affairs or the
United States Government.

REFERENCES
1. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in
receptor desensitization and signaling. Pharmacol Rev . 2001;53:1 - 24.
2. Goodman Jr OB, Krupnick JG, Santini F, et al. Beta-arrestin acts as a clathrin adaptor in
endocytosis of the beta2-adrenergic receptor. Nature . 1996;383:447- 450.
3. Laporte SA, Oakley RH, Zhang J, et al. The beta2-adrenergic receptor/beta arrestin
complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci
USA . 1999;96:3712 - 3717.
4. Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of
c-Src in G protein-coupled receptor- and G b g subunit-mediated activation of mitogen
activated protein kinases. J Biol Chem . 1996;271:19443 - 19450.
5. van Biesen T, Hawes BE, Luttrell DK, et al. Receptor-tyrosine-kinase- and G b g -
mediated MAP kinase activation by a common signalling pathway. Nature .
1995;376:781- 784.
6. Luttrell LM, Ferguson SSG, Daaka Y, et al. b -Arrestin-dependent formation of b 2
adrenergic receptor/Src protein kinase complexes. Science . 1999;283:655- 661.
7. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic recep-
tor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the
pluridimensionality of efficacy. Mol Pharmacol . 2006;70:1575- 1584.
8. Maudsley S, Martin B, Luttrell LM. Perspectives in pharmacology: the origins of diver-
sity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther .
2005;314:485- 494.
9. Luttrell LM. Reviews in molecular biology and biotechnology: transmembrane signal-
ing by G protein-coupled receptors. Mol Biotechnol . 2008;39:239- 264.
10. Luttrell LM, Gesty-Palmer D. Beyond desensitization: physiological relevance of
arrestin-dependent signaling. Pharmacol Rev . 2010;62:305- 330.
11. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Dery O, Bunnett NW. The pro-
liferative and antiapoptotic effects of substance P are facilitated by formation of a
beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA . 2000;97:

11086- 11091.
12. Barlic J, Andrews JD, Kelvin AA, et al. Regulation of tyrosine kinase activation and
granule release through beta-arrestin by CXCRI. Nat Immunol . 2000;1:227 - 233.
13. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated
MAPK scaffold for the activation of JNK3. Science . 2000;290:1574- 1577.
14. DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. Beta-
arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intra-
cellular targeting of activated ERK1/2. J Cell Biol . 2000;148:1267 - 1281.
15. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular
signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA .
2001;98:2449- 2454.
16. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by
ubiquitination of

b 2-adrenergic b -arrestin. Science .

activated receptor and

2001;294:1307- 1313.